title: The evaluation of the immunoexpression of Her2÷neu oncoprotein in ductal carcinoma in situ in association with invasive ductal carcinoma of the breast.
abstract: The identification of breast ductal carcinoma in situ (DCIS) is a factor that increases 8-10 times the risk of developing invasive ductal breast carcinoma (DCI) later. In this study, we evaluated the immunoexpression of the HER2/neu oncoprotein in the DCIS cases associated with DCI, both in situ and in the invasive components. We also studied the Her2/neu immunoreactivity in the cases of DCI having no DCIS association. The positive immunoreactivity (score 3) of the HER2/neu oncoprotein was present in 29 cases of high-grade DCIS having DCI associated, corresponding to the histological types comedo, solid, comedo/solid, and micropapillary. A weak-to-moderate complete membrane staining (score 2+) was determined in five high-grade DCIS and four intermediate-grade DCIS cases, belonging to the types comedo, solid, and micropapillary. The negative immunoreactivity of HER2/neu was identified in 18 cases, most of them being of low grade and belonging to the solid and cribriform types. The invasive component of the analyzed lesions indicated a HER2/neu positive reaction in 50% of lesions having DCI associated and 17.4% of the lesions having no DCIS association. The DCIS-DCI association and the DCIS histological types that were analyzed through the HER2/immunoexpression can stand as prognostic factors for the malignant breast lesions.
authors.affiliation: Department of Pathology, University of Medicine and Pharmacy of Craiova, 66 1 May Ave., Craiova, Romania.
authors.forename: Georgiana Luminiţa
authors.initials: GL
authors.lastname: Fota
authors.forename: A
authors.initials: A
authors.lastname: Stepan
authors.forename: Raluca Niculina
authors.initials: RN
authors.lastname: Ciurea
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D014408:Biomarkers, Tumor / Q000096:biosynthesis*; D001943:Breast Neoplasms / Q000378:metabolism* / Q000473:pathology; D018270:Carcinoma, Ductal, Breast / Q000378:metabolism* / Q000473:pathology; D005260:Female; D006801:Humans; D008875:Middle Aged; D015513:Oncogene Proteins; D011379:Prognosis; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000096:biosynthesis*
chemical_list: D014408:Biomarkers, Tumor; D015513:Oncogene Proteins; D018719:Erb-b2 Receptor Tyrosine Kinases; C508053:ERBB2 protein, human